載入中
NASDAQHealthcareBiotechnology
最新資料
US$1.4392
+US$0.0592 · +4.29%
PDS Biotechnology Corporation is a clinical-stage biopharmaceutical firm dedicated to advancing innovative, multi-functional immunotherapies to combat cancer. Its primary drug candidate, PDS0101 (HPV16), is currently undergoing Phase II clinical trials, positioned as an initial treatment option for recurrent or metastatic head and neck cancer, human papillomavirus (HPV)-associated malignancies, and cervical cancer. The company's developmental pipeline further includes several preclinical product candidates. These comprise PDS0102, utilizing T-cell receptor gamma alternate reading frame protein (TARP) for prostate and breast cancers; PDS0103 (MUC-1) targeting ovarian, colorectal, lung, and breast cancers; and PDS0104, which incorporates Tyrosinase-related protein 2 for the treatment of melanoma. Beyond oncology, PDS Biotechnology is also engaged in developing treatments for infectious diseases, with candidates such as PDS0201 for tuberculosis, PDS0202 as an investigational influenza vaccine, and PDS0203, a vaccine aimed at preventing COVID-19. The company has established strategic partnerships and licensing agreements with notable entities including the National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is headquartered in Florham Park, New Jersey.
一般交易時段
US$1.4392
+US$0.0592 · +4.29%
盤中時間採用ET。市場資料可能有所延遲。
PDS Biotechnology Corporation is a clinical-stage biopharmaceutical firm dedicated to advancing innovative, multi-functional immunotherapies to combat cancer. Its primary drug candidate, PDS0101 (HPV16), is currently undergoing Phase II clinical trials, positioned as an initial treatment option for recurrent or metastatic head and neck cancer, human papillomavirus (HPV)-associated malignancies, and cervical cancer. The company's developmental pipeline further includes several preclinical product candidates. These comprise PDS0102, utilizing T-cell receptor gamma alternate reading frame protein (TARP) for prostate and breast cancers; PDS0103 (MUC-1) targeting ovarian, colorectal, lung, and breast cancers; and PDS0104, which incorporates Tyrosinase-related protein 2 for the treatment of melanoma. Beyond oncology, PDS Biotechnology is also engaged in developing treatments for infectious diseases, with candidates such as PDS0201 for tuberculosis, PDS0202 as an investigational influenza vaccine, and PDS0203, a vaccine aimed at preventing COVID-19. The company has established strategic partnerships and licensing agreements with notable entities including the National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is headquartered in Florham Park, New Jersey.
日內區間
目前US$1.4392
52週區間
目前US$1.4392
盤中時間採用ET。市場資料可能有所延遲。
PDS Biotechnology Corporation is a clinical-stage biopharmaceutical firm dedicated to advancing innovative, multi-functional immunotherapies to combat cancer. Its primary drug candidate, PDS0101 (HPV16), is currently undergoing Phase II clinical trials, positioned as an initial treatment option for recurrent or metastatic head and neck cancer, human papillomavirus (HPV)-associated malignancies, and cervical cancer. The company's developmental pipeline further includes several preclinical product candidates. These comprise PDS0102, utilizing T-cell receptor gamma alternate reading frame protein (TARP) for prostate and breast cancers; PDS0103 (MUC-1) targeting ovarian, colorectal, lung, and breast cancers; and PDS0104, which incorporates Tyrosinase-related protein 2 for the treatment of melanoma. Beyond oncology, PDS Biotechnology is also engaged in developing treatments for infectious diseases, with candidates such as PDS0201 for tuberculosis, PDS0202 as an investigational influenza vaccine, and PDS0203, a vaccine aimed at preventing COVID-19. The company has established strategic partnerships and licensing agreements with notable entities including the National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is headquartered in Florham Park, New Jersey.
日內區間
目前US$1.4392
52週區間
目前US$1.4392
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | — | 5.98萬 USD | 5.73萬 USD | — | — |
| 毛利 | — | −5.98萬 USD | −5.73萬 USD | — | — |
| 研究與開發 | 1902.58萬 USD | 2256.55萬 USD | 2776.2萬 USD | 2943.1萬 USD | 1125.45萬 USD |
| 銷售、一般及管理費用 | 1251.81萬 USD | 1369.59萬 USD | 1528.2萬 USD | 1224.14萬 USD | 1018.48萬 USD |
| 營業費用 | 3154.4萬 USD | 3626.14萬 USD | 4304.5萬 USD | 4167.24萬 USD | 2143.93萬 USD |
| 利息收入 | 121.72萬 USD | 251.5萬 USD | 290.3萬 USD | 93.52萬 USD | 4346 USD |
| 利息支出 | 533.86萬 USD | 467.3萬 USD | 420.6萬 USD | 131.7萬 USD | — |
| 折舊和攤銷 | 2.18萬 USD | 2111.2萬 USD | 5.73萬 USD | 86 USD | 5357 USD |
| 營業利益 | −3154.4萬 USD | −3632.12萬 USD | −4304.5萬 USD | −4167.24萬 USD | −2143.93萬 USD |
| 淨利 | −3449.55萬 USD | −3761.04萬 USD | −4294.2萬 USD | −4085.49萬 USD | −1691.85萬 USD |
公司資料更新於 2026年10月12日。
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
